KR102790232B1 - Cd70 병용 요법 - Google Patents

Cd70 병용 요법 Download PDF

Info

Publication number
KR102790232B1
KR102790232B1 KR1020207021983A KR20207021983A KR102790232B1 KR 102790232 B1 KR102790232 B1 KR 102790232B1 KR 1020207021983 A KR1020207021983 A KR 1020207021983A KR 20207021983 A KR20207021983 A KR 20207021983A KR 102790232 B1 KR102790232 B1 KR 102790232B1
Authority
KR
South Korea
Prior art keywords
seq
ser
amino acid
acid sequence
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207021983A
Other languages
English (en)
Korean (ko)
Other versions
KR20200110658A (ko
Inventor
루크 반 롬페이
마한 모시르
피오트르 자브록키
팀 들라이예
Original Assignee
아르제넥스 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르제넥스 비브이 filed Critical 아르제넥스 비브이
Publication of KR20200110658A publication Critical patent/KR20200110658A/ko
Application granted granted Critical
Publication of KR102790232B1 publication Critical patent/KR102790232B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207021983A 2018-01-16 2019-01-16 Cd70 병용 요법 Active KR102790232B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800649.4A GB201800649D0 (en) 2018-01-16 2018-01-16 CD70 Combination Therapy
GB1800649.4 2018-01-16
PCT/EP2019/051058 WO2019141732A1 (en) 2018-01-16 2019-01-16 Cd70 combination therapy

Publications (2)

Publication Number Publication Date
KR20200110658A KR20200110658A (ko) 2020-09-24
KR102790232B1 true KR102790232B1 (ko) 2025-04-03

Family

ID=61256176

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207021983A Active KR102790232B1 (ko) 2018-01-16 2019-01-16 Cd70 병용 요법

Country Status (22)

Country Link
US (2) US11530271B2 (enExample)
EP (2) EP3740504B9 (enExample)
JP (2) JP7511479B2 (enExample)
KR (1) KR102790232B1 (enExample)
CN (1) CN111836830B (enExample)
AU (1) AU2019209503B2 (enExample)
BR (1) BR112020014321A2 (enExample)
CA (1) CA3086448A1 (enExample)
DK (1) DK3740504T5 (enExample)
EA (1) EA202091714A1 (enExample)
ES (1) ES2956258T3 (enExample)
FI (1) FI3740504T3 (enExample)
GB (1) GB201800649D0 (enExample)
HU (1) HUE063783T2 (enExample)
IL (1) IL276103A (enExample)
LT (1) LT3740504T (enExample)
MX (1) MX2020007606A (enExample)
PL (1) PL3740504T3 (enExample)
PT (1) PT3740504T (enExample)
SG (1) SG11202006007YA (enExample)
WO (1) WO2019141732A1 (enExample)
ZA (1) ZA202003986B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596979B (zh) 2011-03-16 2018-01-26 阿尔金-X有限公司 针对cd70的抗体
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
MY205933A (en) 2018-09-27 2024-11-21 Celgene Corp Sirp-alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
EP4041394A1 (en) * 2019-09-16 2022-08-17 Novartis AG Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
TW202140037A (zh) * 2020-01-17 2021-11-01 瑞士商諾華公司 組合療法
WO2021226289A2 (en) * 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とｃｄ４７遮断の併用
CN114765061B (zh) * 2021-01-15 2024-12-27 深圳哲源生物科技有限责任公司 Pd-1/pd-l1抑制剂的不良预后的数据处理系统及方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
US20240165229A1 (en) * 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
US20050118656A1 (en) 2001-11-27 2005-06-02 Terrett Jonathan A. Methods for diagnosis and treatment of epithelial-derived cancers
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
US20060134756A1 (en) 2003-03-24 2006-06-22 Wenfeng Xu Anti-IL-20 antibodies and binding partners and methods of using in inflammation
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
EP1799262A4 (en) 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
CA2584157C (en) 2004-10-22 2014-10-14 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006113747A2 (en) 2005-04-19 2006-10-26 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
WO2007011856A2 (en) 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
BRPI0617549A2 (pt) 2005-09-26 2011-07-26 Medarex Inc anticorpo monoclonal humano isolado, anticorpo monoclonal humano isolado ou uma porÇço ligante ao antÍgeno do mesmo, composiÇço, imunoconjugado, molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-cd70, mÉtodo para tratar ou prevenir uma doenÇa, mÉtodo para tratar uma doenÇa autoimune em um indivÍduo, mÉtodo para tratar uma inflamaÇço em um indivÍduo, mÉtodo para tratar uma infecÇço viral em um indivÍduo, anticorpo ou porÇço ligante ao antÍgeno do mesmo e uso de um anticorpo ou de uma porÇço ligante ao antÍgeno do mesmo
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
EP2097534A4 (en) 2006-12-14 2010-05-12 Medarex Inc HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
US20110190157A1 (en) 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
BR112012002854B1 (pt) 2009-08-10 2020-02-18 Samumed, Llc Composto ou sal farmaceuticamente aceitável, composição farmacêutica e uso dos mesmos
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
CN102665759B (zh) 2009-11-19 2015-09-30 默克雪兰诺有限公司 人源化抗il-22ra抗体
CA2785964C (en) 2009-12-29 2021-03-30 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
KR101846590B1 (ko) 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
MX354450B (es) 2011-01-19 2018-03-05 Cantargia Ab Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
CN103596979B (zh) 2011-03-16 2018-01-26 阿尔金-X有限公司 针对cd70的抗体
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
ES2806146T3 (es) 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
CA2867299C (en) 2012-03-15 2019-08-27 John Chen Human anti-cd27 antibodies, methods, and uses
EP2827878A1 (en) 2012-03-21 2015-01-28 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
AU2012382875B2 (en) 2012-06-15 2017-04-20 Curegenix Inc. Compound as WNT signaling inhibitor, composition, and use thereof
WO2014033252A1 (en) 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
CA3004138A1 (en) * 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US20220136068A1 (en) 2019-03-06 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
IL300996A (en) 2020-08-29 2023-04-01 argenx BV Treatment method for patients with reduced sensitivity to BCL-2 inhibitor
AU2021358768A1 (en) 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Also Published As

Publication number Publication date
CN111836830B (zh) 2024-08-23
MX2020007606A (es) 2020-09-03
IL276103A (en) 2020-08-31
AU2019209503B2 (en) 2025-08-28
EP3740504B1 (en) 2023-07-19
AU2019209503A1 (en) 2020-07-09
US12180293B2 (en) 2024-12-31
GB201800649D0 (en) 2018-02-28
EA202091714A1 (ru) 2020-10-15
LT3740504T (lt) 2023-09-11
DK3740504T3 (da) 2023-10-23
WO2019141732A1 (en) 2019-07-25
US11530271B2 (en) 2022-12-20
KR20200110658A (ko) 2020-09-24
EP3740504B9 (en) 2023-11-22
EP4275702A2 (en) 2023-11-15
BR112020014321A2 (pt) 2020-12-08
JP2021510736A (ja) 2021-04-30
CA3086448A1 (en) 2019-07-25
EP3740504A1 (en) 2020-11-25
PT3740504T (pt) 2023-10-04
JP7511479B2 (ja) 2024-07-05
JP2024037765A (ja) 2024-03-19
DK3740504T5 (da) 2024-07-15
ZA202003986B (en) 2025-04-30
ES2956258T3 (es) 2023-12-18
WO2019141732A9 (en) 2020-05-22
CN111836830A (zh) 2020-10-27
PL3740504T3 (pl) 2024-01-29
US20190241668A1 (en) 2019-08-08
HUE063783T2 (hu) 2024-01-28
US20240002523A1 (en) 2024-01-04
EP4275702A3 (en) 2024-02-28
SG11202006007YA (en) 2020-08-28
FI3740504T3 (fi) 2023-10-11

Similar Documents

Publication Publication Date Title
KR102790232B1 (ko) Cd70 병용 요법
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
KR102650524B1 (ko) 항-sirp-알파 항체 및 그의 사용 방법
CN103703024B (zh) 能够与人和非人cd3结合的cd3结合分子
EP3148580B1 (en) Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
US20170233472A1 (en) ROR1-Binding Molecules, and Methods of Use Thereof
US20250115676A1 (en) ADAM9-Binding Molecules, and Methods of Use Thereof
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
AU2017248626A1 (en) New anti-SIRPa antibodies and their therapeutic applications
HK40095839A (en) Cd70 combination therapy
WO2023150677A2 (en) Anti-cd38 binding molecules and uses thereof
HK40031662A (en) Cd70 combination therapy
HK40031662B (en) Cd70 combination therapy
HK40033769A (en) Cd70 combination therapy
HK40033769B (zh) Cd70组合疗法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200728

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220103

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231120

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241020

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20250108

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20250217

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250328

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250328

End annual number: 3

Start annual number: 1

PG1601 Publication of registration